PGNX Share Price

Open 8.93 Change Price %
High 9.19 1 Day 0.00 0.00
Low 8.84 1 Week -0.26 -2.82
Close 8.96 1 Month 0.01 0.11
Volume 540167 1 Year 4.67 108.86
52 Week High 9.78
52 Week Low 3.61
PGNX Important Levels
Resistance 2 9.28
Resistance 1 9.15
Pivot 9.00
Support 1 8.77
Support 2 8.64
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
DRYS 1.87 0.00%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LINE 0.18 12.50%
ATEA 1.90 11.76%
ATEA 1.90 11.76%
KITD 0.30 11.11%
SGYPU 10.75 10.26%
LPHI 0.24 9.09%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Progenics Pharmaceuticals Inc. (NASDAQ: PGNX)

PGNX Technical Analysis 5
As on 13th Jan 2017 PGNX Share Price closed @ 8.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5.96 & Strong Buy for SHORT-TERM with Stoploss of 8.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
PGNX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
PGNX Other Details
Segment EQ
Market Capital 99951264.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.progenics.com
PGNX Address
PGNX
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-789-2800
Fax: 914-789-2817
PGNX Latest News
Interactive Technical Analysis Chart Progenics Pharmaceuticals Inc. ( PGNX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Progenics Pharmaceuticals Inc.
PGNX Business Profile
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.